검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BCG (Bacillus Calmette-Guérin, Bacillus Calmette-Guérin (BCG)) Noah Hahn, M.D.·Urothelial Carcinoma ORR 23.1% |
|---|---|
Overview Program | Bacillus Calmette-Guérin (BCG) |
Overview Company | Noah Hahn, M.D. |
Overview Modality | ANTIBODY |
Overview Target | Urothelial Carcinoma |
Overview Indication | Urothelial Carcinoma; Bladder Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | PD-1 expression on CD8 + T cells follow |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.. Bacillus Calmette Guerin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) remains a difficult clinical setting in which radical cystectomy offers the most reliable oncologic control but is not feasible or acceptable for many patients. This review examines contemporary bladder-preserving st… |
Clinical Primary efficacy | ORR 23.1% |
Clinical ORR | 23.1% |
Clinical Result source | ClinicalTrials.gov NCT02901548 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | BCG (Bacillus Calmette-Guérin, Bacillus Calmette-Guérin (BCG)) Noah Hahn, M.D.·Urothelial Carcinoma ORR 23.1% |
|---|---|
Overview Program | Bacillus Calmette-Guérin (BCG) |
Overview Company | Noah Hahn, M.D. |
Overview Modality | ANTIBODY |
Overview Target | Urothelial Carcinoma |
Overview Indication | Urothelial Carcinoma; Bladder Cancer |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
MoA Biomarker | PD-1 expression on CD8 + T cells follow |
PK/PD Species | Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Bladder-Preserving Platforms for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer.. Bacillus Calmette Guerin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) remains a difficult clinical setting in which radical cystectomy offers the most reliable oncologic control but is not feasible or acceptable for many patients. This review examines contemporary bladder-preserving st… |
Clinical Primary efficacy | ORR 23.1% |
Clinical ORR | 23.1% |
Clinical Result source | ClinicalTrials.gov NCT02901548 |
Clinical Data Tier / Score | A · 42 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교